Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Unaudited Financial Results for the Quarter and half year ended September 30, 202122-10-2021
22-10-2021
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2021
The Board of Directors at its meeting held on October 22, 2021 has inter- alia approved the Unaudited Financial Results for the Quarter and half year ended September 30, 202122-10-2021
Gland Pharma Ltd - 543245 - Shareholding for the Period Ended September 30, 2021
Gland Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here16-10-2021
Gland Pharma Ltd - 543245 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sampath Kumar PallerlamudiDesignation :- Company Secretary and Compliance Officer12-10-2021
Gland Pharma gets tentative nod from USFDA for generic Sugammadex injection
Drug firm Gland Pharma on Friday said it has received a tentative nod from the US health regulator for generic Sugammadex injection, which is indicated for reversing the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to patients during surgery. The company "has received tentative approval from the United States Food and Drug Administration (USFDA) for Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial...", Gland Pharma said in a regulatory filing. The product is the generic version of Merck Sharp & Dohme Corp's Bridion injection, 100 mg/mL, it added. The company will launch the product through its marketing partner on receipt of final approval, Gland Pharma said. According to IQVIA, the Sugammadex injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial had US sales of about USD 615 million for 12 months ended April 2021, it added. Sugammadex injection is used to reverse the effects of the muscle relaxants...08-10-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Product Tentative Approval : US FDA tentative approval for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.08-10-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 64,700 shares under ESOP07-10-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q2FY2205-10-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement pertaining to the Notice of Board Meeting.30-09-2021
Buy Gland Pharma: target of Rs 4400: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4400 in its research report dated September 29, 2021.30-09-2021